Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
type 2 diabetes, Alzheimer's and Novo Nordisk
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients.
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.
Alzheimer’s Breakthrough: Popular Diabetes Drug Ozempic Linked to Much Lower Risk
Semaglutide may reduce Alzheimer's risk in type 2 diabetes patients, with research suggesting significant protective benefits compared to other diabetes drugs. Researchers at Case Western Reserve School of Medicine have found that semaglutide,
Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says
A new study reveals that the active ingredient in drugs like Ozempic and Wegovy could lower the risk of developing Alzheimer’s disease.
Popular diabetes and weight-loss drug may reduce risk of Alzheimer's disease
Researchers at the Case Western Reserve School of Medicine have found that when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and weight-loss drug, may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).
Novo’s Ozempic Linked to Reduced Alzheimer’s Diagnoses
Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.
Ozempic May Reduce the Risk of Alzheimer’s. That’s Huge for Novo Nordisk.
Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.
Novo Nordisk's semaglutide could also be effective against Alzheimer's
A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also be effective in tackling Alzheimer's dis
6d
on MSN
Wegovy Maker Novo Nordisk Says New Pill Shows 14% Reduction in Heart Attacks, Strokes in Diabetic Patients
The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...
3d
on MSN
Diabetes patients worry about insulin shortages as Ozempic use skyrockets
The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...
4h
on MSN
Eli Lilly gets nod to launch weight-loss drug in Hong Kong - Bloomberg News
Eli Lilly expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News ...
MedPage Today on MSN
4d
Scripts for GLP-1, SGLT2 Drugs on the Rise in Type 1 Diabetes Patients
GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...
3d
on MSN
As insulin shortages persist, what diabetes patients can do
Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...
UPI
10d
Study: Men using diabetes drug metformin won't increase birth defect risk
A
new
, reassuring study finds that men can take the
diabetes
drug
metformin without worrying that their offspring will ...
4d
Healthy Returns: Weight loss, diabetes drugs may reduce alcohol and opioid use
GLP-1 drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by around half. Meanwhile, tech companies are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback